Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.07
SNN's Cash to Debt is ranked lower than
56% of the 394 Companies
in the Global Medical Devices industry.

( Industry Median: 1.73 vs. SNN: 0.07 )
SNN' s 10-Year Cash to Debt Range
Min: 0.07   Max: No Debt
Current: 0.07

Equity to Asset 0.54
SNN's Equity to Asset is ranked higher than
62% of the 376 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. SNN: 0.54 )
SNN' s 10-Year Equity to Asset Range
Min: 0.26   Max: 0.74
Current: 0.54

0.26
0.74
Interest Coverage 81.00
SNN's Interest Coverage is ranked higher than
63% of the 213 Companies
in the Global Medical Devices industry.

( Industry Median: 155.63 vs. SNN: 81.00 )
SNN' s 10-Year Interest Coverage Range
Min: 7.79   Max: 94
Current: 81

7.79
94
F-Score: 5
Z-Score: 4.25
M-Score: -2.80
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 17.63
SNN's Operating margin (%) is ranked higher than
90% of the 384 Companies
in the Global Medical Devices industry.

( Industry Median: 6.58 vs. SNN: 17.63 )
SNN' s 10-Year Operating margin (%) Range
Min: 12.6   Max: 23.22
Current: 17.63

12.6
23.22
Net-margin (%) 11.86
SNN's Net-margin (%) is ranked higher than
87% of the 384 Companies
in the Global Medical Devices industry.

( Industry Median: 5.11 vs. SNN: 11.86 )
SNN' s 10-Year Net-margin (%) Range
Min: 8.9   Max: 26.81
Current: 11.86

8.9
26.81
ROE (%) 12.73
SNN's ROE (%) is ranked higher than
86% of the 380 Companies
in the Global Medical Devices industry.

( Industry Median: 5.84 vs. SNN: 12.73 )
SNN' s 10-Year ROE (%) Range
Min: 13.81   Max: 47.34
Current: 12.73

13.81
47.34
ROA (%) 8.46
SNN's ROA (%) is ranked higher than
87% of the 394 Companies
in the Global Medical Devices industry.

( Industry Median: 3.49 vs. SNN: 8.46 )
SNN' s 10-Year ROA (%) Range
Min: 8.21   Max: 22.82
Current: 8.46

8.21
22.82
ROC (Joel Greenblatt) (%) 38.84
SNN's ROC (Joel Greenblatt) (%) is ranked higher than
90% of the 393 Companies
in the Global Medical Devices industry.

( Industry Median: 12.42 vs. SNN: 38.84 )
SNN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 30.61   Max: 70.26
Current: 38.84

30.61
70.26
Revenue Growth (%) 1.00
SNN's Revenue Growth (%) is ranked higher than
65% of the 307 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. SNN: 1.00 )
SNN' s 10-Year Revenue Growth (%) Range
Min: -19.7   Max: 54
Current: 1

-19.7
54
EBITDA Growth (%) -2.40
SNN's EBITDA Growth (%) is ranked higher than
74% of the 281 Companies
in the Global Medical Devices industry.

( Industry Median: -1.20 vs. SNN: -2.40 )
SNN' s 10-Year EBITDA Growth (%) Range
Min: -10.6   Max: 52.5
Current: -2.4

-10.6
52.5
EPS Growth (%) -5.40
SNN's EPS Growth (%) is ranked higher than
69% of the 272 Companies
in the Global Medical Devices industry.

( Industry Median: 1.70 vs. SNN: -5.40 )
SNN' s 10-Year EPS Growth (%) Range
Min: -25.9   Max: 55.7
Current: -5.4

-25.9
55.7
» SNN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

SNN Guru Trades in Q3 2013

Jim Simons 104,200 sh (+104.31%)
David Dreman 106,371 sh (+6.56%)
Pioneer Investments 38,402 sh (unchged)
John Hussman 19,500 sh (unchged)
Ken Fisher 1,048,381 sh (-0.12%)
» More
Q4 2013

SNN Guru Trades in Q4 2013

Ken Fisher 1,055,926 sh (+0.72%)
Pioneer Investments 38,402 sh (unchged)
John Hussman 19,500 sh (unchged)
Jim Simons 80,600 sh (-22.65%)
David Dreman 66,654 sh (-37.34%)
» More
Q1 2014

SNN Guru Trades in Q1 2014

David Dreman 78,118 sh (+17.2%)
Jim Simons 84,200 sh (+4.47%)
John Hussman 19,500 sh (unchged)
Pioneer Investments 38,402 sh (unchged)
Ken Fisher 994,111 sh (-5.85%)
» More
Q2 2014

SNN Guru Trades in Q2 2014

Louis Moore Bacon 30,000 sh (New)
Mario Gabelli 9,650 sh (New)
Jim Simons 143,000 sh (+69.83%)
Ken Fisher 1,361,425 sh (+36.95%)
Steven Cohen 204,800 sh (unchged)
John Hussman 19,500 sh (unchged)
David Dreman 74,877 sh (-4.15%)
Pioneer Investments 33,902 sh (-11.72%)
» More
» Details

Insider Trades

Latest Guru Trades with SNN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ken Fisher 2014-06-30 Add 36.95%0.07%$29.27 - $38.91 $ 31.34-4%3403562.5
Mario Gabelli 2014-06-30 New Buy$29.27 - $38.91 $ 31.34-4%24125
David Dreman 2013-12-31 Reduce -37.34%0.22%$24.02 - $28.74 $ 31.3419%166635
John Hussman 2012-12-31 Add 56%0.01%$20.41 - $22.26 $ 31.3447%48750
Ken Fisher 2012-09-30 Reduce -30.79%0.07%$19.84 - $22.37 $ 31.3449%2571732.5
Ken Fisher 2012-06-30 Reduce -28.11%0.08%$18.04 - $20.41 $ 31.3463%3715700
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 28.00
SNN's P/E(ttm) is ranked higher than
82% of the 417 Companies
in the Global Medical Devices industry.

( Industry Median: 51.90 vs. SNN: 28.00 )
SNN' s 10-Year P/E(ttm) Range
Min: 11.46   Max: 40.01
Current: 28

11.46
40.01
P/B 3.61
SNN's P/B is ranked higher than
67% of the 417 Companies
in the Global Medical Devices industry.

( Industry Median: 3.25 vs. SNN: 3.61 )
SNN' s 10-Year P/B Range
Min: 2.32   Max: 8.3
Current: 3.61

2.32
8.3
P/S 3.31
SNN's P/S is ranked higher than
67% of the 417 Companies
in the Global Medical Devices industry.

( Industry Median: 3.05 vs. SNN: 3.31 )
SNN' s 10-Year P/S Range
Min: 1.65   Max: 4.83
Current: 3.31

1.65
4.83
PFCF 36.41
SNN's PFCF is ranked higher than
83% of the 416 Companies
in the Global Medical Devices industry.

( Industry Median: 623.33 vs. SNN: 36.41 )
SNN' s 10-Year PFCF Range
Min: 12.57   Max: 169.1
Current: 36.41

12.57
169.1
EV-to-EBIT 20.68
SNN's EV-to-EBIT is ranked higher than
82% of the 417 Companies
in the Global Medical Devices industry.

( Industry Median: 35.69 vs. SNN: 20.68 )
SNN' s 10-Year EV-to-EBIT Range
Min: 8.8   Max: 107.6
Current: 20.68

8.8
107.6
PEG 7.81
SNN's PEG is ranked higher than
89% of the 417 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. SNN: 7.81 )
SNN' s 10-Year PEG Range
Min: 0.45   Max: 11.95
Current: 7.81

0.45
11.95
Shiller P/E 23.22
SNN's Shiller P/E is ranked higher than
93% of the 417 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. SNN: 23.22 )
SNN' s 10-Year Shiller P/E Range
Min: 16.4   Max: 46.12
Current: 23.22

16.4
46.12
Current Ratio 2.21
SNN's Current Ratio is ranked higher than
65% of the 394 Companies
in the Global Medical Devices industry.

( Industry Median: 2.70 vs. SNN: 2.21 )
SNN' s 10-Year Current Ratio Range
Min: 0.8   Max: 2.75
Current: 2.21

0.8
2.75
Quick Ratio 1.17
SNN's Quick Ratio is ranked higher than
56% of the 394 Companies
in the Global Medical Devices industry.

( Industry Median: 2.04 vs. SNN: 1.17 )
SNN' s 10-Year Quick Ratio Range
Min: 0.45   Max: 1.62
Current: 1.17

0.45
1.62

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.78
SNN's Dividend Yield is ranked higher than
71% of the 183 Companies
in the Global Medical Devices industry.

( Industry Median: 1.29 vs. SNN: 2.78 )
SNN' s 10-Year Dividend Yield Range
Min: 0.77   Max: 2.31
Current: 2.78

0.77
2.31
Dividend Payout 0.46
SNN's Dividend Payout is ranked higher than
94% of the 417 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. SNN: 0.46 )
SNN' s 10-Year Dividend Payout Range
Min: 0.3   Max: 4.17
Current: 0.46

0.3
4.17
Dividend growth (3y) 19.30
SNN's Dividend growth (3y) is ranked higher than
87% of the 104 Companies
in the Global Medical Devices industry.

( Industry Median: 10.10 vs. SNN: 19.30 )
SNN' s 10-Year Dividend growth (3y) Range
Min: -54.8   Max: 19.3
Current: 19.3

-54.8
19.3
Yield on cost (5-Year) 3.81
SNN's Yield on cost (5-Year) is ranked higher than
85% of the 186 Companies
in the Global Medical Devices industry.

( Industry Median: 1.58 vs. SNN: 3.81 )
SNN' s 10-Year Yield on cost (5-Year) Range
Min: 1.72   Max: 5.17
Current: 3.81

1.72
5.17
Share Buyback Rate -0.60
SNN's Share Buyback Rate is ranked higher than
79% of the 286 Companies
in the Global Medical Devices industry.

( Industry Median: -0.90 vs. SNN: -0.60 )
SNN' s 10-Year Share Buyback Rate Range
Min: 23.5   Max: -26.3
Current: -0.6

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 70.21
SNN's Price/Tangible Book is ranked higher than
53% of the 417 Companies
in the Global Medical Devices industry.

( Industry Median: 5.50 vs. SNN: 70.21 )
SNN' s 10-Year Price/Tangible Book Range
Min: 4.07   Max: 166.63
Current: 70.21

4.07
166.63
Price/DCF (Projected) 1.82
SNN's Price/DCF (Projected) is ranked higher than
87% of the 417 Companies
in the Global Medical Devices industry.

( Industry Median: 28.89 vs. SNN: 1.82 )
SNN' s 10-Year Price/DCF (Projected) Range
Min: 1.04   Max: 14.88
Current: 1.82

1.04
14.88
Price/Median PS Value 1.17
SNN's Price/Median PS Value is ranked higher than
71% of the 417 Companies
in the Global Medical Devices industry.

( Industry Median: 1.10 vs. SNN: 1.17 )
SNN' s 10-Year Price/Median PS Value Range
Min: 0.59   Max: 1.82
Current: 1.17

0.59
1.82
Price/Graham Number 9.27
SNN's Price/Graham Number is ranked higher than
70% of the 417 Companies
in the Global Medical Devices industry.

( Industry Median: 6.95 vs. SNN: 9.27 )
SNN' s 10-Year Price/Graham Number Range
Min: 1.55   Max: 18.01
Current: 9.27

1.55
18.01
Earnings Yield (Greenblatt) 4.80
SNN's Earnings Yield (Greenblatt) is ranked higher than
73% of the 313 Companies
in the Global Medical Devices industry.

( Industry Median: 5.00 vs. SNN: 4.80 )
SNN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.9   Max: 11.3
Current: 4.8

0.9
11.3
Forward Rate of Return (Yacktman) 4.67
SNN's Forward Rate of Return (Yacktman) is ranked higher than
82% of the 319 Companies
in the Global Medical Devices industry.

( Industry Median: 1.54 vs. SNN: 4.67 )
SNN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 3.9   Max: 54
Current: 4.67

3.9
54

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:SN..UK, NPW1.Germany, NPWA.Germany, SNNUF.USA
Smith & Nephew PLC, together with its subsidiaries, is engaged in developing, manufacturing, marketing and selling medical devices in the sectors of Orthopaedics, Endoscopy and Advanced Wound Management. Its three operating segments are Orthopaedics, Endoscopy and Advanced Wound Management. Orthopaedic comprises reconstruction, trauma and clinical therapies products. Orthopaedic reconstruction implants include hip, knee and shoulder joints as well as ancillary products such as bone cement. Orthopaedic trauma fixation products consist of internal and external devices and other products, including shoulder fixation and orthobiological materials used in the stabilisation of severe fractures and deformity correction procedures. Endoscopy business develops and commercialises endoscopic (minimally invasive surgery) techniques, educational programmes and value-added services for surgeons to treat and repair soft tissue and articulating joints. The business focuses on the arthroscopy sector of the endoscopy market. Advanced Wound Management business offers a range of products from initial wound bed preparation through to full wound closure. These products are targeted at chronic wounds associated with the older population, such as pressure sores and venous leg ulcers. There are also products for the treatment of wounds such as burns and invasive surgery that impact the wider population. The group operates in the Europe, United States, Africa, Asia, Australasia and other America.
» More Articles for NYSE:SNN

Headlines

Articles On GuruFocus.com
3 Dividend Kings From The U.K. I Love To Buy Aug 21 2014 
Stryker Corporation (SYK) Dividend Stock Analysis Jan 11 2013 
5 Highly Predictable Mid-/Large-Caps with ROC Over 15% Apr 21 2012 
The Best Dividends on April 18, 2012 Apr 18 2012 
5 Healthcare Stocks to Consider Today Mar 21 2012 
medical Feb 29 2012 
Stryker Corp. (SYK) Dividend Stock Analysis Dec 16 2011 
comment on SNN Nov 08 2011 
predictable hussma Nov 08 2011 
predictable hussman Nov 01 2011 

More From Other Websites
3 Stocks Pushing The Health Services Industry Lower Oct 15 2014
Smith & Nephew launches the EVOS™ MINI Plating System for complex long bone fractures at... Oct 15 2014
Deutsche Bank Appointed as Successor Depositary Bank for the NYSE-Listed American Depositary Receipt... Oct 01 2014
3 Neil Woodford Plays On Ageing Populations: AstraZeneca plc, Smith & Nephew plc And Capita PLC Sep 25 2014
Will Smith & Nephew Gain on D-RAD SMART PACK Launch? Sep 19 2014
New D-RAD SMART PACK™ System from Smith & Nephew is designed to reduce costs and improve... Sep 18 2014
SNN, ALXN And ACT, 3 Health Care Stocks Pushing The Sector Lower Sep 17 2014
3 Health Services Stocks Nudging The Industry Higher Sep 10 2014
Zacks Industry Outlook Highlights: Zimmer Holdings, Medtronic, Covidien, Stryker and Smith & Nephew Aug 27 2014
Needham: Stryker Deal Not Dead For Smith & Nephew Aug 12 2014
Mark D. Perrin, the CEO of InVivo Therapeutics Corporation (NVIV), Interviews with The Wall Street... Aug 01 2014
Health firms time their earnings right, see gains after the market carnage Aug 01 2014
Smith & Nephew scores a HAT-TRICK with its entry into the high-growth hammer toe repair market Jul 31 2014
Health Services Stocks On The Rise With Help From 3 Stocks Jul 15 2014
Stryker Continues Growth Spree via Acquisitions Jul 14 2014
Smith & Nephew Ink Robotic Surgical Deal with Blue Belt Tech Jul 11 2014
Smith & Nephew enters commercial agreement to bring robotic navigation to the JOURNEY UNI Knee... Jul 10 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK